B1344 ameliorates non-alcoholic steatohepatitis in HFCD-HF/G-induced mice: exploring the therapeutic efficacy and mechanism of a novel FGF21 analogue

已取消 20 由 xiaoshen 发布于 2025/9/2 16:44:30

DOI:10.1016/j.ejphar.2025.177874
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/j.ejphar.2025.177874

其它数据库

Abstract：The endocrine cytokine, fibroblast growth factor 21 (FGF21), shows therapeutic potential for non-alcoholic steatohepatitis (NASH) but has pharmacokinetic limitations. B1344 is a modified PEG

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:International Union of Crystallography (IUCr)Solid–solid phase transformation of aspirin at high pressures and room temperatures